Metformin Induced Vitamin B$_{12}$ Deficiency among Type 2 Diabetes Mellitus Patients

Viswa S, Sivasakthi K*, Monitta Robinson D, Hariharn V

Department of Pharmacy Practice, JKKM MRF’s Annai JKK Sampoorni Ammal College of Pharmacy, Komarapalayam, Tamil Nadu, INDIA.

ABSTRACT

Metformin is the most frequently prescribed medication in the management of Type 2 Diabetes Mellitus. It is widely approved that it suppresses hepatic glucose production and improves insulin signalling mainly in muscle, hepatic and adipose tissue. On long term use, metformin therapy leads to Vitamin B$_{12}$ deficiency and anemia. Several studies shows that long term metformin use reduce the Vitamin B$_{12}$ levels and particularly taken in a dose greater than 2000 mg/day and for a period exceeding 4 years. The prevalence is increased with increase in dose and duration of metformin use. Peripheral neuropathy may be the only clinical presentation of Vitamin B$_{12}$ deficiency, without haematological signs and symptoms. The diagnostic tests like serum Vitamin B$_{12}$ and holo -TC-11 test measure the circulating part of Vitamin while homocysteine and MMA are the biomarkers of metabolic Vitamin B$_{12}$ deficiency that show elevated levels when the Vitamin is deficient at the cellular level. Currently there are no guidelines for the supplementation and appropriate dose of Vitamin B$_{12}$ for diabetic patients on metformin but the treatment of Vitamin B$_{12}$ deficiency includes monthly injections of Vitamin B$_{12}$ or large daily therapeutic doses (1000mcg) of Vitamin B$_{12}$ prophylactically administered calcium carbonate (1.2gms daily). This article demonstrates that regular monitoring of Vitamin B$_{12}$ should be done especially in patients receiving metformin therapy for longer duration at high dosage and Vitamin B$_{12}$ supplementation prophylactically or at least annually to prevent the complications of Vitamin B$_{12}$ deficiency.

Key words: Type 2 Diabetes Mellitus, Metformin, Homocysteine, Vitamin B$_{12}$ deficiency, Peripheral neuropathy.

INTRODUCTION

Metformin, an oral hypoglycemic agent is the most frequently prescribed medication in the management of Type 2 Diabetes Mellitus (T2DM). All guidelines, including the European Association for the Study of Diabetes (EASD) and American Diabetes Association (ADA) focus on metformin as the first line treatment option along with lifestyle intervention for hyperglycaemic management in T2DM. Metformin may also be used to treat other conditions involving insulin resistance and polycystic ovary syndrome (PCOS).

Metformin is widely approved that it suppress hepatic glucose production and improves insulin signalling mainly in muscle, hepatic and adipose tissue. The main side effects of metformin include GI disturbance such as diarrhoea and vomiting, hypoglycaemia and lactic acidosis. On long term use, metformin therapy leads to Vitamin B$_{12}$ deficiency and anemia. Vitamin B$_{12}$ is a vital nutrient for health. It plays an important role in the functioning of the brain and nervous system and in the formation of red blood cells. In addition to anemia, Vitamin B$_{12}$ deficiency may increase the severity of peripheral neuropathy in patients with T2DM. Furthermore, because Vitamin B$_{12}$ Participates in most important pathway of homocysteine (Hcy) metabolism, a reduction in Vitamin B$_{12}$ would increase plasma concentrations of Hcy, which is strongly linked to cardiovascular disease in patients with T2DM and PCOS. This review aims to describe the Vitamin B$_{12}$ deficiency induced by metformin among T2DM patients and it importance to prevent further complications by Vitamin B$_{12}$ supplementation.
Viswa, et al.: Metformin Induced Vitamin B12 Deficiency

History and Background
Metformin, a cornerstone medication, used to manage T2DM with estimates which is routinely prescribed to 120 million diabetic patients around the world. In 1971, it was surprising knowing that the first article (Tomkin et al.) describes metformin associated with Vitamin B12 malabsorption.

Despite the confirmed association between metformin and Vitamin B12 deficiency, the real size of the problem is not yet properly quantified. Previous studies have shown that the prevalence of metformin induced Vitamin B12 deficiency varied greatly and ranged between 5.8% and 52%. Such a wide range may be attributed to difference in cut points chosen to define the deficiency, participants mean age, study setting, metformin dose and duration of use.

Peripheral neuropathy may be the only clinical presentation of Vitamin B12 deficiency, without haematological signs and symptoms. The long term use of metformin, mediated by Vitamin B12 deficiency, may contribute to increasing the substantial burden of peripheral neuropathy in T2DM patients.

Prevalence of Vitamin B12 deficiency among T2DM patients
Several studies shows that long term metformin use reduce the Vitamin B12 levels and particularly taken in a dose greater than 2000 mg/day and for a period exceeding 4 years. Comparing the obtained prevalence of metformin associated Vitamin B12 deficiency from earlier epidemiological studies is not straightforward and should consider several factors. Moreover, the biomarkers used to define the deficiency, together with their cut-offs, can greatly affect the value of prevalence estimate.

Table 1 shows the prevalence estimates and certain characteristics of the studies that used Vitamin B12 deficiency cutoff points of 148 or 150 pmol/L. The table reveals study-related factors with potential to affect the obtained prevalence, including mean participants age, mean metformin daily dose, study settings, mean metformin duration of use and whether participants with renal impairment were excluded. Special attention should also be paid to the mean ages in different studies as Vitamin B12 levels decreases with age. Variations in doses and durations of metformin use can also impact the final prevalence values.

Effect of metformin on Vitamin B12 level
Metformin prevents the absorption of Vitamin B12 in the ileum and this is caused by inhibition of calcium dependent channels in the ileum. It is known that prolonged use of metformin cause Vitamin B12 deficiency by this mechanism.

Ko S-H et al. shows patients with Vitamin B12 deficiency had a longer duration of metformin use (p<0.001), a larger daily dose of metformin (p<0.001) than the patients without Vitamin B12 deficiency. There was a significant lower Vitamin B12 concentrations among those patients receiving 1000mg/day to 2000mg/day than those receiving 1000mg.

DeJager et al. provided the strongest evidence of metformin associated low Vitamin B12 levels by conducting 4.3 years duration randomized controlled trial. The trial reported a 19% metformin associated reduction in Vitamin B12 levels.

Liu Q et al. a meta-analysis also confirmed that metformin induces a reduction in Vitamin B12 levels. This study reported the positive association between the metformin dose and the lowering of the Vitamin concentrations.

Diagnosis of Vitamin B12 deficiency
The diagnostic tests like serum Vitamin B12 and holo-TC- 11 test measure the circulating part of Vitamin while homocysteine and MMA are the biomarkers of metabolic Vitamin B12 deficiency that show elevated levels when the Vitamin is deficient at the cellular level. The more accurate biomarkers have their own sensitivity and specificity limitations.

Serum Vitamin B12 test
The sensitivity of the serum Vitamin B12 test in assessing the Vitamin status is generally high. Several studies shows that Vitamin B12 levels <148 pmol/L have a sensitivity that exceeds 95% in patients with megaloblastic anemia. Bolann et al. used >50% post-therapy decline in MMA as a gold standard to define Vitamin B12 but the specificity of serum Vitamin B12 test is low. Clarke et al. applied strict MMA criteria of >450 and >750 nmol/L as reference tests and found that serum Vitamin B12 <200 pmol/L had specificities of 72% and 75% respectively. The low serum Vitamin B12 levels were falsely reported in pregnancy and folate deficiency.

Jeffery et al. reported that high TC-I levels account for 8% of cases with elevated serum Vitamin B12 levels. People of black ethnicity tend to show higher circulatory levels of TC-I and Vitamin B12. The Vitamin B12 concentrations are elevated also in renal disease patients.
Table 1: Clinical studies measured the prevalence of metformin – Vitamin B\textsubscript{12} deficiency with their diagnostic cut-off points of 148 or 150 pmol/L and other sample and study characteristics.

| Study                  | Obtained prevalence | Mean age (years) | Mean metformin dose (mg) | Mean metformin duration (years) | Study settings                                      | Exclusion of renally-impaired patients |
|------------------------|---------------------|------------------|--------------------------|-------------------------------|----------------------------------------------------|--------------------------------------|
| DeJager et al.         | 9.9%                | 64               | 2050                     | 4.3                           | Outpatient clinics, the Netherlands                 | Yes                                  |
| Reinstatler et al.     | 5.8%                | 63.4             | NA                       | 5'                            | NHANES, United States                               | Yes                                  |
| Hermann et al.         | 8%                  | 58.2             | 2200                     | 5.2                           | Outpatient clinic, Sweden                            | Yes                                  |
| Liu et al.             | 29%                 | 79.7             | NA                       | NA                            | Geriatric outpatient clinic, Hong Kong             | No                                   |
| Beulens et al.         | 28.1%               | 61.6             | 1306                     | 5.3                           | Primary care centre, the Netherlands                | No                                   |
| DeGroot-kamphuis et al.| 14.1%               | 62.6             | NA                       | 4.9'                          | Outpatient clinic, the Netherlands                 | No                                   |
| Ahmed et al.           | 28.1%               | 58.5             | 2400                     | 9.6                           | Outpatient diabetes clinics of 2 tertiary hospitals, South Africa | Yes                                  |

*median value; NHANES: National Health and Nutrition Examination Survey

MMA Test

Vitamin B\textsubscript{12} under the catalysis of the enzyme methylmalonyl-CoA mutase, synthesizes succinyl-CoA from methylmalonyl-CoA in the mitochondria. Deficiency of Vitamin B\textsubscript{12} thus results in elevated MMA levels. Thus measuring MMA levels provides a more accurate estimation of the cellular status of Vitamin B\textsubscript{12} compared with the Vitamin's serum levels. Elevated MMA test has >95% sensitivity to Vitamin B\textsubscript{12} deficiency in patients with pernicious anemia.\textsuperscript{24} In such overt deficiencies, sensitivity of MMA elevation is slightly better than that of low Vitamin B\textsubscript{12} levels.\textsuperscript{25}

Wile DJ et al. a case control study reported higher MMA levels in T2DM patient who were taking metformin compared to the group not taking metformin and also reported a correlation between cumulative dose of the medication and MMA levels for the first time.\textsuperscript{8}

Pfeiffer et al. used the low cut off point of 210 nmol/L as a physiologic choice based on MMA levels in Vitamin B\textsubscript{12} depleted individuals. Usually MMA test cut offs ranging between 210 and 480 nmol/L are used to define Vitamin B\textsubscript{12} deficiency. This represents there is a maximal inhibition of MMA levels by administering Vitamin B\textsubscript{12}.\textsuperscript{26}

The antibiotics have the ability to reduce MMA levels suggests a role for the gut bacteria that produce propionic acid, the precursor of MMA.\textsuperscript{27} Therefore, the specificity of the MMA test is uncertain and the test is not qualified for use as a gold standard for defining Vitamin B\textsubscript{12} deficiency.

HOLO TC II Test

Vitamin B\textsubscript{12} circulates in plasma bound to TC I (70-80%) and TC II carrier proteins (20-30%) to form a metabolically inert complex. The portion attached to TC II protein is known as holo-TC II. Chen et al. found that the metabolic status of Vitamin B\textsubscript{12} was a major determinant of holo-TC II serum levels and also concluded that the absorption status of Vitamin B\textsubscript{12} are influenced by serum holo-TC II levels.\textsuperscript{28}

Several studies suggested that the levels of holo TC II are affected by folate disorders, use of oral contraceptives, myelodysplasia, certain haematological disorders and alcoholism.\textsuperscript{29-31} Mild renal insufficiency has a modest impact on serum Vitamin B\textsubscript{12} and holo-TC II levels unlike its effect on MMA and homocysteine concentrations.\textsuperscript{32}

Homocysteine test

The MS enzyme catalyses the transfer of a methyl group from methyl-tetrahydrofolate to homocysteine to result in the formation of tetrahydrofolate and methionine, utilizing Vitamin B\textsubscript{12} as a cofactor. Thus, elevated homocysteine concentrations are associated with Vitamin B\textsubscript{12} deficiency and homocysteine may be used as a test to assess Vitamin B\textsubscript{12} metabolic status.

McPartlin J et al. recommends setting cut offs for homocysteine levels by considering age and folate fortification status. For folate fortified communities, it recommends 12 micromol/L and 16 micromol/L for those aged 15-20 micromol/L for those aged 15-65 years and >65 years, respectively if not folate fortification implemented, the cut-offs of 15 and 20 micromol/L was recommended.\textsuperscript{33}
Metformin users where found to have slightly higher homocysteine levels than non-users. De Jager et al. a randomized controlled trial of 4.3 years treatment with metformin resulted in a minor statistically significant increase in homocysteine concentrations.

Falsely positive renal failure, old age, Vitamin B5 and Vitamin B2 deficiencies can also cause increased homocysteine concentrations.

**Clinical manifestations of Vitamin B12 deficiency**

Vitamin B12 deficiency is clinically important because it is a reversible cause of bone marrow failure and demyelinating nerve disease. Thus haematological manifestations include macrocytosis and megaloblastic anaemia which may be associated with other signs and symptoms of deficiency such as pancytopenia, glossitis, gastrointestinal dysfunction, psychosis or neurological disorders. Neurological signs and symptoms may take many forms, including peripheral neuropathy which generally manifests as numbness and paresthesia, optic neuropathy and neuropsychiatric disorders such as chronic fatigue syndrome, mood disorders or depressive symptoms.

Vitamin B12 deficiency may also result in improper bowel motility, which manifests as mild constipation or diarrhoea and loss of bowel or bladder control may develop. The deficiency may impair immune response and low bone mineral density.

Neuropathic pain from Vitamin B12 deficiency should be differentiated from that of diabetic neuropathy. So diabetic neuropathy can be confirmed by electromyography or nerve conduction tests.

**Clinical consequence of metformin induced Vitamin B12 deficiency**

Peripheral neuropathy is a primary complication of T2DM and a direct manifestation of Vitamin B12 deficiency. It was recently investigated by five observational studies with conflicting results. Three studies reported no association; two reported increased neuropathy among metformin-exposed patients. Neuropsychiatric manifestations such as depression and cognitive impairment were linked with low Vitamin B12 levels. Two recent studies reported that the Vitamin B12 deficiency among metformin treated patients was associated with worsened cognitive performance and increased risk of depression.

But none of the studies on metformin associated low Vitamin B12 have not reported any significant impact on haematological findings like Haemoglobin concentrations, prevalence of anaemia, mean corpuscular volume or macrocytosis as a primary objective.

**Management of Vitamin B12 deficiency**

Currently there are no guidelines for the supplementation and appropriate dose of Vitamin B12 for diabetic patients on metformin. Treatment of Vitamin B12 deficiency includes monthly injections of Vitamin B12 or large daily therapeutic doses (1000 mcg) of Vitamin B12, prophylactically administered calcium carbonate (1.2 gms daily). In severe cases, discontinuation of metformin therapy is recommended. The dosing pattern of Vitamin B12 depends on cause of the deficiency and the severity of the disease. Vitamin B12 can be supplemented in various forms like hydroxocobalamin, methylcobalamin and cyanocobalamin. However studies have shown that methylcobalamin is better retained in the body than its cyanide containing sibling, cyanocobalamin. Multivitamin use is convenient, non-invasive, inexpensive and generally effective in increasing serum Vitamin B12 concentrations but it is insufficient for diabetic patients taking metformin. Kancherla et al. found that patients receiving metformin therapy who also used oral multivitamin supplements had a 50% higher serum Vitamin B12 or about 161 pmol/L higher serum concentrations, compared to those patients who did not use multivitamin supplements. Only 4% of those taking multivitamin supplements had sub normal Vitamin B12 concentration compared with 15% among non-multivitamin supplement users. On the other hand, Reinstatlex et al. concluded that 6 mcg per day of Vitamin B12 found in most multivitamin supplements is insufficient. Diabetic patients who ingested less than 6 mcg per day of Vitamin B12 from supplements had nearly 8 times higher risk of deficiency of this Vitamin compared to those who ingested a dose greater than 25 mcg per day or higher. Thus, a long term use of oral Vitamin B12 supplementation a dose of 25 mcg per day might be needed to maintain adequate Vitamin B12 status among these individuals, patients who use other medications such as aspirin or those that affect gastric acidity may needed to utilize supplements with higher doses (E.g. 100 mcg or 250 mcg). The same may be true of elderly patients with diabetes.

**CONCLUSION**

Vitamin B12 deficiency occurs more frequently in patients with type 2 diabetes with longer duration of metformin use and in those taking larger amounts of metformin. Several studies have recently investigated that metformin...
induced Vitamin B$_{12}$ deficiency ability to cause or worsen peripheral neuropathy in T2DM patients and the high prevalence obtained with increase in dose and duration. This article demonstrates that regular monitoring of Vitamin B$_{12}$ should be done especially in patients receiving metformin therapy for longer duration at high dosage and Vitamin B$_{12}$ supplementation prophylactically or at least annually to prevent the complications of Vitamin B$_{12}$ deficiency.

ACKNOWLEDGEMENT

We are grateful to our Principal, Vice-principal and HOD, Department of Pharmacy Practice, JKK Sampoornani Anmal College of Pharmacy for their valuable contribution and consistent encouragement.

CONFLICT OF INTEREST

The authors declare no conflict of interest

ABBREVIATIONS

T2DM: Type 2 Diabetes Mellitus; PCOS: Polycystic ovary syndrome; Hcy: Homocysteinate; MMA: Methylmalonic acid; HOLO TC II: Vitamin B$_{12}$ bound transcobalamin-II.

REFERENCES

1. American Diabetes Association Standards of Medical Care in Diabetes. Diabetes Care. 2016.
2. LaMarca A, Artensio AC, Stabile G, Volpe A. Metformin treatment of PCOS during adolescence and the reproductive period. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2005;121(1):3-7.
3. Naftei A, Ferrarin E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review. Diabetologia. 2006;49(3):434-41.
4. Stumvoll M, Naftei N, Perrelli G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes-mellitus. New England Journal of Medicine. 1996;333(9):550-4.
5. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. British Journal of Diabetes and Vascular Disease. 2001;1(1):28-36.
6. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. New England Journal of Medicine. 1998;338(4):265-6.
7. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and Vitamin B$_{12}$ Deficiency in the Diabetes Prevention Program Outcomes Study: Diabetes Prevention Program Research Group. Journal of Clinical Endocrinology and Metabolism. 2016;101(4):1754-61.
8. Wile DJ, Toth C. Association of metformin, elevated homocysteine and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010;33(1):156-61.
9. Hoogeveen EK, Kostense PJ, Bekk PJ, Mackaay AJ, Jakobs C, et al. Hyperhomocysteinemia Is Associated With an Increased Risk of Cardiovascular Disease, Especially in Non–Insulin-Dependent Diabetes Mellitus A Population Based Study. Arteriosclerosis, Thrombosis and Vascular Biology. 1998;18(1):133-8.
10. Vrbikova J, Bickova M, Taltova J, Hill M, Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Experimental and Clinical Endocrinology and Diabetes. 2002;110(2):74-6.
11. Viollet B, Guizou B, Sansz GN, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clinical Science. 2012;122(6):253-70.
12. Tomlin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B$_{12}$ status of patients on long-term metformin therapy. British Medical Journal. 1971;2(5763):685-7.
13. Ahmed MA, Muntingh G, Rheeder P. Vitamin B$_{12}$ deficiency in metformin-treated type-2 diabetes patients, prevalence and association with peripheral neuropathy. BMC Pharmacology and Toxicology. 2016;17(1):44.
14. Heathman EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine. 1991;70(4):229-45.
15. Chapman LE, Darling AL, Brown JE. Association between metformin and Vitamin B (12) deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes and Metabolism. 2016;42(5):316-27.
16. Ko SH, et al. Association of Vitamin B$_{12}$ and Metformin in Type 2 Diabetes. Journal of Korean Medical Science. 2014;29(7):965-72.
17. DeJager J, Kooij A, Lehert P, Wulffije MG, DenKolik JV, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of Vitamin B$_{12}$ deficiency: Randomised placebo controlled trial. BMJ. 2010;340:c2181.
18. Liu G, Li S, Quan H, Li J. Vitamin B$_{12}$ status in metformin treated patients: Systematic review. PLoS One. 2014;9(6):e100379.
19. Carmel R. Biomarker (Vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications and performance characteristics of cobalamin, methylmalonic acid and holotranscobalamin II. American Journal of Clinical Nutrition. 2011;94(1):348S-58S.
20. Stabler SP, Marcell PD, Podell ER, Allen RH, Lindenbaum J. Assay of methylmalonic acid in the serum of patients with cobalamin deficiency using capillary chromatography-mass spectrometry. Journal of Clinical Investigation. 1996;77(5):1606-12.
21. Bolann BJ, Solli JD, Sknee J, Grottum KA, Loraas A, Stokkeland M, et al. Evaluation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid. Chemical Medicine. 2000;46(11):1744-50.
22. Clarke R, Sherliker P, Hin H, Nexo E, Hvas AM, Schneede J, et al. Detection of Vitamin B$_{12}$ deficiency in older people by measuring Vitamin B$_{12}$, or the active fraction of Vitamin B$_{12}$, holotranscobalamin II. Clinical Chemistry. 2007;53(5):963-70.
23. Jeffery J, Millar H, Mackenzie P, Fafie-Wilson M, Hamilton M, Ayling RM. An IgG complexed form of Vitamin B$_{12}$ is a common cause of elevated serum concentrations. Clinical Biochemistry. 2010;43(1-2):82-8.
24. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations. American Journal of Hematology. 1990;34(2):99-107.
25. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ. Biochemical indicators of B Vitamin status in the US population after folic acid fortification: Results from the National Health and Nutrition Examination Survey 1999-2000. American Journal of Clinical Nutrition. 2005;82(2):442-50.
26. Sentongo TA, Azzam R, Charrow J. Vitamin B$_{12}$ status, methylmalonic academia and bacterial overgrowth in short bowel syndrome. Journal of Pediatric Gastroenterology and Nutrition. 2009;48(4):495-7.
27. Quadros EV. Advances in the understanding of cobalamin assimilation and metabolism. British Journal of Haematology. 2010;148(2):195-204.
28. Chen X, Remacha AF, Sarda MP, Carmel R. Influence of cobalamin deficiency compared with that of cobalamin absorption on serum holotranscobalamin II. American Journal of Clinical Nutrition. 2005,81(1):110-4.
29. Morkbak AL, Heimdal RM, Emmens K, Molloy A, Hvas AM, Schneede J, et al. Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project. Clinical Chemistry and Laboratory Medicine. 2005;43(10):1058-64.
30. Carmel R. The distribution of endogenous cobalamin among cobalamin-binding proteins in the blood in normal and abnormal states. American Journal of Clinical Nutrition.1985;41(4):713-9.
31. Wickramasinghe SN, Ratnayaka ID. Limited value of serum holotranscobalamin II measurements in the differential diagnosis of macrocytosis. Journal of Clinical Pathology. 1996;49(9):755-8.
32. Loka G, Kostkina P, Irjala K, Lopponen M, Isahoro R, Kivela SL, et al. Renal impairment compromises the use of total homocysteine and methylmalonic acid but not total Vitamin B$_{12}$ and holotranscobalamin in screening for Vitamin
B₁₂ deficiency in the aged. Clinical Chemistry and Laboratory Medicine. 2007;45(2):197-201.
33. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: An expert opinion. Clinical Chemistry. 2004;50(1):3-32.
34. Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Does metformin increase the serum total homocysteine level in non-insulindependent diabetes mellitus?. Journal of Internal Medicine. 1997;242(5):389-94.
35. Briani C, Dalla TC, Citton V, Manara R, Pompanin S, Binotto G, et al. Cobalamin deficiency: Clinical picture and radiological findings. Nutrients. 2013;5(11):4521-39.
36. Sethi N, Robiotti E, Sadan Y. Neurological Manifestations of Vitamin B₁₂ Deficiency. The Internet Journal of Nutrition and Wellness. 2004;2(1):1-7.
37. Tiemeier H, Tuuli HRV, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B₁₂, folate and homocysteine in depression: the Rotterdam Study. American Journal of Psychiatry. 2002;159(12):2099-101.
38. Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, et al. Low plasma Vitamin B₁₂ is associated with lower BMD: The Framingham Osteoporosis Study. Journal of Bone and Mineral Research. 2005;20(1):152-6.
39. Singh AK, Kumar A, Karmakar D, Jha RK. Association of B₁₂ deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. Journal of Postgraduate Medicine. 2013;59(4):253-7.
40. DeGroot-Kamphuis DM, Dijk PRV, Groenier KH, Houweling ST, Bilo HJ, Kleefstra N. Vitamin B₁₂ deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Netherlands Journal of Medicine. 2013;71(7):386-90.
41. Chen S, Lansdown AJ, Moat SJ, Ellis R, Goringe A, Dunstan FDJ, et al. An observational study of the effect of metformin on B₁₂ status and peripheral neuropathy. British Journal of Diabetes and Vascular Disease. 2012;12(1):189-93.
42. Biemans E, Hart HE, Rutten GE, Cuellar RVG, Kooijman-Buiting AM, Beulens JW. Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. Acta Diabetologica. 2014;52(2):383-93.
43. Tiemeier H, Tuuli HRV, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B₁₂, folate and homocysteine in depression: the Rotterdam Study. American Journal of Psychiatry. 2002;159(12):2099-101.
44. Moore E, Mander A, Arnes D, Came R, Sanders K, Watters D. Cognitive impairment and Vitamin B₁₂: A Review. International Psychogeriatric Association. 2012;24(4):541-56.
45. Iftikhar R, Kamran SM, Qadir A, Iqbal Z, Bin UH. Prevalence of Vitamin B₁₂ deficiency in patients of type 2 diabetes mellitus on metformin: A case control study from Pakistan. Pan African Medical Journal. 2013;16:67.
46. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of Vitamin B(12) deficiency in patients receiving metformin. Archives of Internal Medicine. 2006;166(18):1975-9.
47. Bauman WA, Shaw S, Jastykele E, Spungen AM, Herbert V. Increased intake of calcium reverses Vitamin B₁₂ malabsorption induced by metformin. Diabetes Care. 2000;23(9):1227-31. PMID: 10977010
48. Bell DS. Metformin-induced Vitamin B₁₂ deficiency presenting as a peripheral neuropathy. South Medical Journal. 2010;103(3):265-7. doi: 10.1097/SMJ.0b013e3181ce0e4d PMID: 20134380
49. Kancherla V, Garn JV, Zakai NA, Williamson RS, Cashion WT. Multivitamin Use and Serum Vitamin B₁₂ Concentrations in Older-Adult Metformin Users in REGARDS, 2003-2007. PLoS One. 2016;11(8):e0160802.
50. Reinstatler L, Qi YP, Williamson RS, Garn JV, ROakley GP. Association of biochemical B(12) deficiency with metformin therapy and Vitamin B(12) supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2012;35(2):327-33.
51. Van OMG, Laheji RJ, Peters WH, Jansen JB, Verheugt FW, BACH study. Association of aspirin use with Vitamin B₁₂ deficiency (results of the BACH study). American Journal of Cardiology. 2004;94(7):975-7.